Fouad Azzam, Ph.D.

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

About DOTS DOTS (Detection On the Spot) has a mission to make people’s lives better through a disruptive diagnostics platform that gives them information to make better decisions. We are developing a food allergen detector for consumers to test food prior to consumption. Privately held, VC funded, DOTS is a consumer products company with an emphasis on teamwork and innovation. Based in Natick, Massachusetts.

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.

We are excited to announce that Simplify Medical has joined NuVasive, the largest spine focused company in the world. Our team has worked for more than 10 years on bringing to life the most clinically effective technology in the cTDR procedure segment, and we’re excited about how this acquisition positions us to make an even bigger impact in patient lives. 

Rainier Therapeutics is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development.

Rainier Therapeutics is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development.

Celladon (Nasdaq: CLDN) is a public biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.

Robots are powering the next innovation surge in Industry. Harvest Automation is a material handling company that develops and manufactures robots to address some of the most challenging issues facing the world. Backed by a team of world-class robotics innovators, Harvest Automation has released the first flexible, scalable robots for Agriculture and Distribution & Fulfillment.   Harvest enables operators to create a sustainable workforce of robots working safely alongside people. Our robots increase productivity in a cost effective, flexible and scalable way.

Seahorse is the flagship brand of Agilent's Cell Analysis division. Seahorse's Extracellular Flux (XF) technology is the gold standard in cell-based metabolic assays. Scientists worldwide use XF Analyzers to understand the role of energy metabolism in obesity, diabetes, aging, cancer, immunology, cardiovascular function and drug safety. Seahorse is also the leader in cost effective custom crafted labware solutions for scientists and OEM's. With unparalleled design expertise, Seahorse's labware designers and mold craftsmen provide fast turn around for all custom labware requirements. A complete line of filtration plates, reagent reservoirs, and high throughput compound storage plates are available for lab automation and high-throughput screening needs.

At Neuros, our goal is to help amputees with chronic phantom and residual limb pain find relief, decrease pain-induced opioid dependency, improve mental health and restore quality-of-life. We are at work on a novel technology to help make this ambition a reality. Pending FDA Clearance - Investigational Device - Not Intended for Sale

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

EQT Life Sciences, formerly LSP, is one of Europe’s largest and most experienced healthcare investors, targeting innovative life sciences and health care companies.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

About DOTS DOTS (Detection On the Spot) has a mission to make people’s lives better through a disruptive diagnostics platform that gives them information to make better decisions. We are developing a food allergen detector for consumers to test food prior to consumption. Privately held, VC funded, DOTS is a consumer products company with an emphasis on teamwork and innovation. Based in Natick, Massachusetts.